Safety in Ovarian Cancer for Average-Risk Women - Analysis

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2026
This study is designed to evaluate the safety, specificity, and downstream diagnostic burden of the Evident™ Ovarian Cancer Screening Test in average-risk postmenopausal women. Participants will provide a blood sample for screening and will be followed for approximately 12 months to assess test safety, specificity, downstream diagnostic procedures, and ovarian cancer outcomes.
Epistemonikos ID: ccfd22068e75d41842aaf0074d9b5f87578246b2
First added on: Oct 14, 2026